Tharimmune Inc (THAR)

$2.56 +0.11 (4.49%)
Market Cap 89.29M
Revenue (ttm) 0.00
Net Income (ttm) -12.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 240,300
Avg Vol 1,588,404
Day's Range N/A - N/A
Shares Out 36.45M
Stochastic %K 82%
Beta 1.43
Analysts Strong Buy
Price Target $17.00

Company Profile

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for immunology and inflammation conditions in the United States. It is involved in the development of TH104 for the proposed indication of temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders entering and area contaminated with opioids, as well as is in phase 2 study in patients with chronic pruritus in primary bili...

Industry: Biotechnology
Sector: Healthcare
Phone: 732-889-3111
Address:
34 Shrewsbury Avenue, Suite 1C, Red Bank, United States
QuantKingpinV2
QuantKingpinV2 Dec. 25 at 12:51 PM
$THAR A transition phase is underway where operating consistency matters more than rapid expansion. Commercial adoption must become steadier to neutralize skepticism around sustainability. Successful iteration can create optionality that is not yet fully priced. Investors will likely wait for pattern recognition before re‑committing capital.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 24 at 11:32 PM
$THAR
0 · Reply
leon_dedrick
leon_dedrick Dec. 24 at 4:29 PM
$THAR
0 · Reply
leon_dedrick
leon_dedrick Dec. 24 at 4:28 PM
$THAR The burn to mint ratio on Canton Network It's expected by 2030 it will be at an equilibrium (balanced)
0 · Reply
leon_dedrick
leon_dedrick Dec. 24 at 3:30 PM
$THAR Canton Coin (CC) Volume is looking really good
0 · Reply
UnpopularPicks
UnpopularPicks Dec. 24 at 11:04 AM
$THAR Future price discovery depends on how progress validates the underlying thesis beyond narrative appeal. Momentum requires evidence, not projections.
0 · Reply
Ron_Burn
Ron_Burn Dec. 22 at 11:05 AM
$THAR has bottomed out
0 · Reply
leon_dedrick
leon_dedrick Dec. 20 at 2:06 PM
$THAR 6:15 mark til the end Guys Canton may have close to a quadrillion on chain already https://youtu.be/CK2BbwahLPo?si=8ZN_qAhf69xzqkDg
0 · Reply
mini_plenty
mini_plenty Dec. 17 at 4:45 PM
$THAR Partnership Announcement: DTCC (Depository Trust & Clearing Corporation), Digital Asset Holdings, and Canton Network are collaborating to tokenize U.S. Treasury securities custodied at DTC. In 2024, DTCC’s subsidiaries processed securities transactions valued at U.S. $3.7 quadrillion. https://www.dtcc.com/news/2025/december/17/dtcc-and-digital-asset-partner-to-tokenize-dtc-custodied-us-treasury-securities
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 17 at 3:53 PM
$THAR Current Stock Price: $2.35
0 · Reply
Latest News on THAR
Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network

Dec 18, 2025, 8:15 AM EST - 7 days ago

Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network

Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy

Dec 12, 2025, 8:15 AM EST - 13 days ago

Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy

Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids

Nov 13, 2025, 8:05 AM EST - 6 weeks ago

Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids

Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy

Nov 6, 2025, 4:16 PM EST - 6 weeks ago

Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy

Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy

Nov 3, 2025, 9:04 AM EST - 7 weeks ago

Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy

Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

Sep 4, 2025, 8:01 AM EDT - 4 months ago

Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl

Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments

Aug 20, 2025, 8:00 AM EDT - 4 months ago

Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

Aug 13, 2025, 8:01 AM EDT - 4 months ago

Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

Aug 5, 2025, 8:00 AM EDT - 5 months ago

Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

Aug 4, 2025, 8:00 AM EDT - 5 months ago

Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

Jul 23, 2025, 10:15 PM EDT - 5 months ago

Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

Jun 17, 2025, 8:01 AM EDT - 6 months ago

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

May 6, 2025, 8:01 AM EDT - 8 months ago

Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

May 1, 2025, 8:01 AM EDT - 8 months ago

Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Apr 30, 2025, 8:01 AM EDT - 8 months ago

Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Apr 28, 2025, 8:01 AM EDT - 8 months ago

Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Apr 15, 2025, 9:00 AM EDT - 9 months ago

Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Apr 7, 2025, 8:00 AM EDT - 9 months ago

Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Mar 31, 2025, 8:00 AM EDT - 9 months ago

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Mar 24, 2025, 8:00 AM EDT - 9 months ago

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Mar 4, 2025, 7:00 AM EST - 10 months ago

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology

Tharimmune to Present at the Microcap Conference 2025

Jan 27, 2025, 8:30 AM EST - 11 months ago

Tharimmune to Present at the Microcap Conference 2025

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Dec 16, 2024, 8:00 AM EST - 1 year ago

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Dec 6, 2024, 4:15 PM EST - 1 year ago

Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Nov 18, 2024, 8:00 AM EST - 1 year ago

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Nov 13, 2024, 8:00 AM EST - 1 year ago

Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics

Tharimmune Announces Upcoming Conference Presentations

Nov 4, 2024, 9:00 AM EST - 1 year ago

Tharimmune Announces Upcoming Conference Presentations

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Oct 30, 2024, 8:00 AM EDT - 1 year ago

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Oct 28, 2024, 9:00 AM EDT - 1 year ago

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Sep 30, 2024, 7:00 AM EDT - 1 year ago

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Jul 17, 2024, 8:30 AM EDT - 1 year ago

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Apr 30, 2024, 8:31 AM EDT - 1 year ago

Tharimmune To Participate in Two Upcoming Investor Conferences in May

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Apr 23, 2024, 7:31 AM EDT - 1 year ago

Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

Apr 15, 2024, 8:31 AM EDT - 1 year ago

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

OABI

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Mar 5, 2024, 8:31 AM EST - 1 year ago

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Feb 20, 2024, 8:01 AM EST - 2 years ago

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Feb 5, 2024, 8:30 AM EST - 2 years ago

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Jan 29, 2024, 8:00 AM EST - 2 years ago

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Dec 11, 2023, 8:01 AM EST - 2 years ago

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Nov 30, 2023, 4:01 PM EST - 2 years ago

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Nov 27, 2023, 9:40 PM EST - 2 years ago

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Nov 27, 2023, 8:00 AM EST - 2 years ago

Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC)

Tharimmune Announces 1-for-25 Reverse Stock Split

Nov 17, 2023, 7:00 AM EST - 2 years ago

Tharimmune Announces 1-for-25 Reverse Stock Split

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Nov 6, 2023, 5:35 PM EST - 2 years ago

Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

Sep 22, 2023, 8:30 AM EDT - 2 years ago

Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Sep 11, 2023, 11:51 AM EDT - 2 years ago

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Sep 8, 2023, 2:30 PM EDT - 2 years ago

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

QuantKingpinV2
QuantKingpinV2 Dec. 25 at 12:51 PM
$THAR A transition phase is underway where operating consistency matters more than rapid expansion. Commercial adoption must become steadier to neutralize skepticism around sustainability. Successful iteration can create optionality that is not yet fully priced. Investors will likely wait for pattern recognition before re‑committing capital.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 24 at 11:32 PM
$THAR
0 · Reply
leon_dedrick
leon_dedrick Dec. 24 at 4:29 PM
$THAR
0 · Reply
leon_dedrick
leon_dedrick Dec. 24 at 4:28 PM
$THAR The burn to mint ratio on Canton Network It's expected by 2030 it will be at an equilibrium (balanced)
0 · Reply
leon_dedrick
leon_dedrick Dec. 24 at 3:30 PM
$THAR Canton Coin (CC) Volume is looking really good
0 · Reply
UnpopularPicks
UnpopularPicks Dec. 24 at 11:04 AM
$THAR Future price discovery depends on how progress validates the underlying thesis beyond narrative appeal. Momentum requires evidence, not projections.
0 · Reply
Ron_Burn
Ron_Burn Dec. 22 at 11:05 AM
$THAR has bottomed out
0 · Reply
leon_dedrick
leon_dedrick Dec. 20 at 2:06 PM
$THAR 6:15 mark til the end Guys Canton may have close to a quadrillion on chain already https://youtu.be/CK2BbwahLPo?si=8ZN_qAhf69xzqkDg
0 · Reply
mini_plenty
mini_plenty Dec. 17 at 4:45 PM
$THAR Partnership Announcement: DTCC (Depository Trust & Clearing Corporation), Digital Asset Holdings, and Canton Network are collaborating to tokenize U.S. Treasury securities custodied at DTC. In 2024, DTCC’s subsidiaries processed securities transactions valued at U.S. $3.7 quadrillion. https://www.dtcc.com/news/2025/december/17/dtcc-and-digital-asset-partner-to-tokenize-dtc-custodied-us-treasury-securities
1 · Reply
BillionerOfKing
BillionerOfKing Dec. 17 at 3:53 PM
$THAR Current Stock Price: $2.35
0 · Reply
JohnTrack
JohnTrack Dec. 16 at 9:35 PM
$THAR short brief on the company https://www.rapidticker.com/news/thar-sec-filing-677b2f
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 11 at 11:46 PM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $THAR | Timeframe: 6M / 1D Market Cap: $88.66M • Pattern score: 0.67 • Current price: $2.530 • Peak (window): $7.710 • Trough (post-spike): $2.250 • Pullback: ~70.8% from peak • Move off lows: ~32.8% of peak Stock Plan (educational only) • Entry zone: $2.454 – $2.581 • Scalp target: $2.732 → Est. ROI: ~8.0% • Swing target: $4.048 → Est. ROI: ~60.0% • Protective stop: $2.150 → Risk: ~15.0% below current Options Idea (real chain data only) • Options Idea: No valid real-time option chain data available. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups.com Trending Ticker Watch: $AMC
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 11 at 5:16 AM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $THAR | Timeframe: 6M / 1D Market Cap: $94.27M • Pattern score: 0.71 • Current price: $2.690 • Peak (window): $7.710 • Trough (post-spike): $2.250 • Pullback: ~70.8% from peak • Move off lows: ~34.9% of peak Stock Plan (educational only) • Entry zone: $2.609 – $2.744 • Scalp target: $2.905 → Est. ROI: ~8.0% • Swing target: $4.304 → Est. ROI: ~60.0% • Protective stop: $2.287 → Risk: ~15.0% below current Options Idea (real chain data only) • Options Idea: No valid real-time option chain data available. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $PSKY
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 11 at 3:25 AM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $THAR | Timeframe: 6M / 1D Market Cap: $94.27M • Pattern score: 0.71 • Current price: $2.690 • Peak (window): $7.710 • Trough (post-spike): $2.250 • Pullback: ~70.8% from peak • Move off lows: ~34.9% of peak Stock Plan (educational only) • Entry zone: $2.609 – $2.744 • Scalp target: $2.905 → Est. ROI: ~8.0% • Swing target: $4.304 → Est. ROI: ~60.0% • Protective stop: $2.287 → Risk: ~15.0% below current Options Idea (real chain data only) • Options Idea: No valid real-time option chain data available. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $ULTY
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 11 at 1:44 AM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $THAR | Timeframe: 6M / 1D Market Cap: $94.27M • Pattern score: 0.71 • Current price: $2.690 • Peak (window): $7.710 • Trough (post-spike): $2.250 • Pullback: ~70.8% from peak • Move off lows: ~34.9% of peak Stock Plan (educational only) • Entry zone: $2.609 – $2.744 • Scalp target: $2.905 → Est. ROI: ~8.0% • Swing target: $4.304 → Est. ROI: ~60.0% • Protective stop: $2.287 → Risk: ~15.0% below current Options Idea (real chain data only) • Options Idea: No valid real-time option chain data available. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $SMCI
0 · Reply
SmartOptionsAlert
SmartOptionsAlert Dec. 10 at 11:54 PM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $THAR | Timeframe: 6M / 1D Market Cap: $94.27M • Pattern score: 0.71 • Current price: $2.690 • Peak (window): $7.710 • Trough (post-spike): $2.250 • Pullback: ~70.8% from peak • Move off lows: ~34.9% of peak Stock Plan (educational only) • Entry zone: $2.609 – $2.744 • Scalp target: $2.905 → Est. ROI: ~8.0% • Swing target: $4.304 → Est. ROI: ~60.0% • Protective stop: $2.287 → Risk: ~15.0% below current Options Idea (real chain data only) • Options Idea: No valid real-time option chain data available. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $AMC
0 · Reply
aquibtahseen
aquibtahseen Dec. 10 at 5:43 PM
$THAR no news on this one?
0 · Reply
bionicman1969
bionicman1969 Dec. 5 at 1:50 PM
$THAR Initiated at ACCUMULATE on differentiated Canton Coin plan and privacy financial network growth with major institutions.
0 · Reply
Creative7Trades
Creative7Trades Dec. 5 at 1:27 AM
$DVLT EXTREMELY BULLiSH $SRFM BULLiSH $AMC BULLiSH $THAR BULLiSH sleeping giant fo.. sho
0 · Reply
Creative7Trades
Creative7Trades Dec. 5 at 1:23 AM
$THAR BULLiSH
0 · Reply
aquibtahseen
aquibtahseen Dec. 3 at 6:06 AM
$THAR no news at all ??
0 · Reply
juanagustin2086
juanagustin2086 Nov. 30 at 7:17 PM
$THAR
0 · Reply